Fundraising Fox

AnaCardio

Stockholm, SE · 5 known investors

anacardio.com ↗

AnaCardio is a clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, including its GOAL-HF1 program for patients with Heart Failure and Reduced Ejection Fraction (HFrEF).

BiotechMedical Devices

Investors · 5

3B Future Health FundMonaco · $12M
IndustrifondenStockholm · $1.1M – $4.3M
Novo HoldingsCopenhagen · $1.1M – $54M
Pureos BioventuresPfäffikon
Sound BioventuresMalmö

In the news

Swedish company secures $19M to advance heart failure drug candidate AC01 - ArcticStartuparcticstartup.com · Jan 2025AnaCardio pumps €19 million into heart failure treatment innovation | EU-Startupseu-startups.com · Jan 2025AnaCardio raises $19m in funding round for heart failure candidate - Pharmafilepharmafile.com · Jan 2025Karolinska Development’s portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01globenewswire.com · Jan 2025AnaCardio raises USD 19 million - NLSnordiclifescience.org · Jan 2025AnaCardio raises 150 million SEK in series A round co-led by Industrifonden – Industrifondenindustrifonden.com · Sep 2022

Frequently asked questions

What does AnaCardio do?
AnaCardio is a clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, including its GOAL-HF1 program for patients with Heart Failure and Reduced Ejection Fraction (HFrEF).
Who are AnaCardio's investors?
AnaCardio's investors include 3B Future Health Fund, Industrifonden, Novo Holdings, Pureos Bioventures, Sound Bioventures.
Where is AnaCardio headquartered?
AnaCardio is headquartered in Stockholm, SE.